Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 878 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: IFN Clear all

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Aurora, Colorado • Durham, North Carolina

Conditions: Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Emapalumab, Fludarabine, Hematopoietic Cell Transplantation, Melphalan, Multigated Acquisition Scan, Mycophenolate Mofetil, Questionnaire Administration, Tacrolimus; Procedure · Drug · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PEG-interferon alfa-2b, temozolomide; Biological · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Interventions: CHS-388, Pembrolizumab, Toripalimab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 15 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more

Conditions: Leukocyte Adhesion Deficiency Syndrome
Interventions: Interferon gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
Interventions: Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Bone Marrow Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastric Cancer
Interventions: filgrastim, recombinant interferon alfa, docetaxel, doxorubicin hydrochloride, fluorouracil, hydroxyurea; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 24
States / cities: Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 18 more

Conditions: Myelofibrosis
Interventions: Imetelstat, Best Available Therapy (BAT); Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • New Haven, Connecticut + 9 more

Conditions: Hepatitis C, Chronic
Interventions: PEG-rIL-29, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 29
States / cities: Beverly Hills, California • Coronado, California • La Jolla, California + 26 more

Conditions: Hepatitis C
Interventions: Interferon-alpha; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Tucson, Arizona • Atlanta, Georgia

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 9
States / cities: Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Interferon gamma-1b, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Melanoma
Interventions: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Interferon-gamma 1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Conditions: Hepatitis B
Interventions: JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Essential Thrombocythemia
Interventions: Ropeginterferon alfa-2b, Anagrelide; Biological · Drug
Lead sponsor: PharmaEssentia; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 4
States / cities: Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Hepatitis C
Interventions: Integrated care model, Usual Care Model; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Palo Alto, California • San Diego, California • The Bronx, New York

Search by objective public record fields.

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I

Combination Drug Therapy for Patients With Hepatitis C

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Cytokine Gene Polymorphisms in Bone Marrow Failure

Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes